$PHAS PhaseBio Pharmaceuticals Inc Insider Trading

FREE EMAIL WATCHDOG

Get free email notifications about insider trading in PhaseBio Pharmaceuticals Inc.

  • Your email is safe with us.
  • The service is free and you can unsubscribe at any time.

General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview


Overview of insider trading in PhaseBio Pharmaceuticals Inc. Insider overview, share value development, latest insider transactions and email notifications about new events in PhaseBio Pharmaceuticals Inc for free.

CIK Number: 0001169245
IRS Number: 030375697
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Trading Symbol: PHAS
Company Address: 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN 19355
Phone number: (610) 981-6500
Former name: DT BIOSCIENCES INC, date of change: 2002-03-15
Former name: Phase Biosciences Inc, date of change: 2006-10-13

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp on January 10, 2002 and is headquartered in Malvern, PA.

PhaseBio Pharmaceuticals Inc Latest Insider Transactions

DateTickerCompanyOwnerRelationship Transaction Code Cost ($) Shares Transaction Value ($) Total Shares % Holdings
Jun 04 2021PHASPhaseBio Pharmaceu ...Klein Peter JustinDirectorOption ExerciseA3.5314,00049,42014,000
Jun 04 2021PHASPhaseBio Pharmaceu ...Loewy Caroline MDirectorOption ExerciseA3.5314,00049,42014,000
Jun 04 2021PHASPhaseBio Pharmaceu ...Thorp ClayDirectorOption ExerciseA3.5314,00049,42014,000
May 24 2021PHASPhaseBio Pharmaceu ...York MichaelVP, Corporate Devel ...GrantA2.802,8978,1127,0594.2 K to 7.1 K (+69.61 %)
May 24 2021PHASPhaseBio Pharmaceu ...Arnold Susan ElizabethVP, Preclinical and ...GrantA2.805,25714,72023,24118 K to 23.2 K (+29.23 %)
Feb 09 2021PHASPhaseBio Pharmaceu ...Mow Jonathan PChief Executive Off ...Option ExerciseA4.31234,0001,008,540234,000
Feb 09 2021PHASPhaseBio Pharmaceu ...Hanson KristopherVP, Head of LegalOption ExerciseA4.3136,000155,16036,000
Feb 09 2021PHASPhaseBio Pharmaceu ...Hanson KristopherVP, Head of LegalOption ExerciseA4.3136,000155,16036,000
Feb 09 2021PHASPhaseBio Pharmaceu ...York MichaelVP, Corporate Devel ...Option ExerciseA4.3136,000155,16036,000
Feb 09 2021PHASPhaseBio Pharmaceu ...York MichaelVP, Corporate Devel ...Option ExerciseA4.3136,000155,16036,000
Feb 09 2021PHASPhaseBio Pharmaceu ...Arnold Susan ElizabethVP, Preclinical and ...Option ExerciseA4.3136,000155,16036,000
Feb 09 2021PHASPhaseBio Pharmaceu ...Arnold Susan ElizabethVP, Preclinical and ...Option ExerciseA4.3136,000155,16036,000
Feb 09 2021PHASPhaseBio Pharmaceu ...Sharp John PChief Financial Off ...Option ExerciseA4.3176,500329,71576,500
Feb 09 2021PHASPhaseBio Pharmaceu ...Sharp John PChief Financial Off ...Option ExerciseA4.3176,500329,71576,500
Feb 09 2021PHASPhaseBio Pharmaceu ...Lee John SangChief Medical Offic ...Option ExerciseA4.3176,500329,71576,500

View all PhaseBio Pharmaceuticals Inc insider transactions.